C 10 H 12 ClNOS, monoclinic, P21/n (no. 14), a = 13. 
Experimental details
The C-bound H atoms were geometrically placed (C-H = 0.95-1.00 Å) and refined as riding with U iso (H) = 1.2-1.5 Ueq(C). The N-bound H-atom was located in a difference Fourier map but was refined with a distance restraint of N-H = 0.88 + −0.01 Å, and with U iso (H) set to 1.2 Ueq(N). Owing to poor agreement, a reflection, i.e. (10 0 8), was omitted from the final cycles of refinement.
Comment
The motivation for the preparation of the title compound was the observation that alkoxythiocarbamides, i.e. ROC(=S)N(H)R′ for R/R′ = alkyl/aryl, when complexed to phosphanegold(I), generate bioactive compounds in the context of both cancer [6] and bacterial infection [7] , and the structure determination follows on-going systematic structural investigations in this area [8, 9] .
The molecular structure of iPrOC(=S)N(H)C 6 H4Cl 3 is shown in the Figure ( While there are no direct precedents for the title compound in the crystallographic literature [8, 9] , the structure of the ethoxy derivative has been reported recently [10] . In the latter, the same syn disposition of the thioamide-N-H and thione-S atoms in the molecular structure and supramolecular {· · · HNCS} 2 synthon in the molecular packing are observed. The key difference in structures is found in the relative dispositions of the thione-S and chloro atoms which lie to opposite sides in the molecule of the ethoxy derivative as opposed to the conformation observed in the title compound.
